Janus Kinase Inhibitors: An Innovative Treatment for Alopecia Areata

June 2019 in “ Journal of dermatology ”

Hyun Sun Park, Duk Jun Yu, Oh Sang Kwon

Janus kinase inhibitors JAK inhibitors alopecia areata autoreactive cytotoxic T cells JAK pathway AA

TLDR New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.

The document discussed the potential of Janus kinase (JAK) inhibitors as an innovative treatment for alopecia areata (AA), a common disease with no satisfactory treatment. Research indicated that autoreactive cytotoxic T cells and the JAK pathway play crucial roles in AA's pathogenesis. Several single-arm clinical trials and retrospective studies showed that oral JAK inhibitors were effective and tolerable for moderate to severe AA. However, the document emphasized the need for further placebo-controlled clinical trials to confirm the efficacy and long-term safety of JAK inhibitors.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Cited in this study

10 / 10 results

research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

66 citations , December 2018 in “Dermatology”

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , July 2018 in “Journal of Investigative Dermatology”

Tofacitinib may help treat severe hair loss, but more research is needed.

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations , July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.

research Nail Involvement in Patients with Moderate-to-Severe Alopecia Areata Treated with Oral Tofacitinib

9 citations , May 2018 in “Journal of Dermatological Treatment”

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

$Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series$

research Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series

44 citations , November 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

research Treatment of Alopecia Areata With Tofacitinib

78 citations , June 2017 in “JAMA Dermatology”

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

1 / 1 results

research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child

April 2019 in “International journal of research in dermatology”

A child with rough nails also had hair loss and allergies.

Janus Kinase Inhibitors: An Innovative Treatment for Alopecia Areata

Cited in this study

research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

research Nail Involvement in Patients with Moderate-to-Severe Alopecia Areata Treated with Oral Tofacitinib

research Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series

research Treatment of Alopecia Areata With Tofacitinib

research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

Related

research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child